NeuroPace Inc
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | -$23.7M |
| Operating expenses | $93.6M | $80.8M | $75.3M | $73.3M | $57.2M |
| Cost of revenue | $22.8M | $20.8M | $17.3M | $13.0M | $11.7M |
| Cash from operations | -$11.0M | -$17.9M | -$19.7M | -$36.9M | -$24.6M |
| Capital expenditure | $332,000 | $306,000 | $173,000 | $603,000 | $384,000 |
| Free cash flow | -$11.3M | -$18.3M | -$19.9M | -$37.5M | -$25.0M |
| Share repurchases | $49.5M | $0 | — | $0 | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $105.6M | $94.6M | $107.7M | $114.1M | $133.6M |
| Total liabilities | $86.5M | $86.6M | $87.0M | $79.3M | $60.1M |
Shares outstanding 34.1M · Free float 57.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.